146 related articles for article (PubMed ID: 30396925)
61. Dysregulated expression of cell surface glycoprotein CDCP1 in prostate cancer.
Yang L; Dutta SM; Troyer DA; Lin JB; Lance RA; Nyalwidhe JO; Drake RR; Semmes OJ
Oncotarget; 2015 Dec; 6(41):43743-58. PubMed ID: 26497208
[TBL] [Abstract][Full Text] [Related]
62. Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells.
Maehara S; Tanaka S; Shimada M; Shirabe K; Saito Y; Takahashi K; Maehara Y
Int J Cancer; 2004 Nov; 112(2):184-9. PubMed ID: 15352029
[TBL] [Abstract][Full Text] [Related]
63. A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells.
Duxbury MS; Ito H; Benoit E; Waseem T; Ashley SW; Whang EE
Cancer Res; 2004 Jun; 64(11):3987-93. PubMed ID: 15173012
[TBL] [Abstract][Full Text] [Related]
64. CDCP1 (CUB domain containing protein 1) is a potential urine-based biomarker in the diagnosis of low-grade urothelial carcinoma.
Liu CL; Tsai HW; Peng SL; Chang CP; Chang YH; Huang HS
PLoS One; 2023; 18(3):e0281873. PubMed ID: 36862682
[TBL] [Abstract][Full Text] [Related]
65. Evidence that cell surface localization of serine protease activity facilitates cleavage of the protease activated receptor CDCP1.
He Y; Reid JC; He H; Harrington BS; Finlayson B; Khan T; Hooper JD
Biol Chem; 2018 Sep; 399(9):1091-1097. PubMed ID: 29447112
[TBL] [Abstract][Full Text] [Related]
66. Cub domain-containing protein 1 negatively regulates TGF-β signaling and myofibroblast differentiation.
Noskovičová N; Heinzelmann K; Burgstaller G; Behr J; Eickelberg O
Am J Physiol Lung Cell Mol Physiol; 2018 May; 314(5):L695-L707. PubMed ID: 29351434
[TBL] [Abstract][Full Text] [Related]
67. CUB domain-containing protein 1 (CDCP1) binds transforming growth factor beta family members and increase TGF-β1 signaling pathway.
Predes D; Cruz JVR; Abreu JG; Mendes FA
Exp Cell Res; 2019 Oct; 383(1):111499. PubMed ID: 31302030
[TBL] [Abstract][Full Text] [Related]
68. CDCP1: A promising diagnostic biomarker and therapeutic target for human cancer.
Qi X; Gao J; Li Z; Zhang G; Li J; Fu Y; Cai M; Wang H; Tong T
Life Sci; 2022 Jul; 301():120600. PubMed ID: 35504333
[TBL] [Abstract][Full Text] [Related]
69. Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-blind randomized phase II study.
Hashimoto D; Satoi S; Ishikawa H; Kodera Y; Kamei K; Hirano S; Fujii T; Uemura K; Tsuchida A; Yamada S; Yamamoto T; Hirota K; Sekimoto M
Trials; 2022 Feb; 23(1):135. PubMed ID: 35151367
[TBL] [Abstract][Full Text] [Related]
70. The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility.
Benes CH; Poulogiannis G; Cantley LC; Soltoff SP
Oncogene; 2012 Feb; 31(5):653-63. PubMed ID: 21725358
[TBL] [Abstract][Full Text] [Related]
71. The cell surface glycoprotein CDCP1 in cancer--insights, opportunities, and challenges.
Wortmann A; He Y; Deryugina EI; Quigley JP; Hooper JD
IUBMB Life; 2009 Jul; 61(7):723-30. PubMed ID: 19514048
[TBL] [Abstract][Full Text] [Related]
72. Structural requirements for cub domain containing protein 1 (CDCP1) and Src dependent cell transformation.
Kollmorgen G; Bossenmaier B; Niederfellner G; Häring HU; Lammers R
PLoS One; 2012; 7(12):e53050. PubMed ID: 23300860
[TBL] [Abstract][Full Text] [Related]
73. FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation.
Cui YH; Kim H; Lee M; Yi JM; Kim RK; Uddin N; Yoo KC; Kang JH; Choi MY; Cha HJ; Kwon OS; Bae IH; Kim MJ; Kaushik N; Lee SJ
Oncogene; 2018 Oct; 37(43):5794-5809. PubMed ID: 29973690
[TBL] [Abstract][Full Text] [Related]
74. CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation.
Wright HJ; Hou J; Xu B; Cortez M; Potma EO; Tromberg BJ; Razorenova OV
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6556-E6565. PubMed ID: 28739932
[TBL] [Abstract][Full Text] [Related]
75. Prognostic significance of CUB domain containing protein expression in endometrioid adenocarcinoma.
Mamat S; Ikeda J; Enomoto T; Ueda Y; Rahadiani N; Tian T; Wang Y; Qiu Y; Kimura T; Aozasa K; Morii E
Oncol Rep; 2010 May; 23(5):1221-7. PubMed ID: 20372833
[TBL] [Abstract][Full Text] [Related]
76. Emodin potentiates the antitumor effects of gemcitabine in pancreatic cancer cells via inhibition of nuclear factor-κB.
Liu A; Chen H; Tong H; Ye S; Qiu M; Wang Z; Tan W; Liu J; Lin S
Mol Med Rep; 2011; 4(2):221-7. PubMed ID: 21468555
[TBL] [Abstract][Full Text] [Related]
77. Inactivation of ATF-2 enhances epithelial-mesenchymal transition and gemcitabine sensitivity in human pancreatic cancer cells.
Wu X; Liu Z; Guo K; Ma G; Song S
J Cell Biochem; 2019 Mar; 120(3):4463-4471. PubMed ID: 30367508
[TBL] [Abstract][Full Text] [Related]
78. SRC kinase activator CDCP1 promotes hepatocyte growth factor-induced cell migration/invasion of a subset of breast cancer cells.
Kawase N; Sugihara A; Kajiwara K; Hiroshima M; Akamatsu K; Nada S; Matsumoto K; Ueda M; Okada M
J Biol Chem; 2022 Mar; 298(3):101630. PubMed ID: 35085554
[TBL] [Abstract][Full Text] [Related]
79. CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.
Alajati A; D'Ambrosio M; Troiani M; Mosole S; Pellegrini L; Chen J; Revandkar A; Bolis M; Theurillat JP; Guccini I; Losa M; Calcinotto A; De Bernardis G; Pasquini E; D'Antuono R; Sharp A; Figueiredo I; Nava Rodrigues D; Welti J; Gil V; Yuan W; Vlajnic T; Bubendorf L; Chiorino G; Gnetti L; Torrano V; Carracedo A; Camplese L; Hirabayashi S; Canato E; Pasut G; Montopoli M; Rüschoff JH; Wild P; Moch H; De Bono J; Alimonti A
J Clin Invest; 2020 May; 130(5):2435-2450. PubMed ID: 32250342
[TBL] [Abstract][Full Text] [Related]
80. Prognostic Significance of CDCP1 Expression in Colorectal Cancer and Effect of Its Inhibition on Invasion and Migration.
Chou CT; Li YJ; Chang CC; Yang CN; Li PS; Jeng YM; Chen ST; Kuo ML; Lin IC; Lin BR
Ann Surg Oncol; 2015 Dec; 22(13):4335-43. PubMed ID: 25820997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
